UroGen Pharma URGN Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's short- and long-term operating lease liabilities?
- UroGen Pharma (URGN) reported short- and long-term operating lease liabilities of -$53K in Q1 2026.
- How has UroGen Pharma's short- and long-term operating lease liabilities changed year-over-year?
- UroGen Pharma's short- and long-term operating lease liabilities increased by 92.8% year-over-year, from -$738K to -$53K.
- What is the long-term trend for UroGen Pharma's short- and long-term operating lease liabilities?
- Over 2 years (2022 to 2024), UroGen Pharma's short- and long-term operating lease liabilities has grown at a -4.1% compound annual growth rate (CAGR), from -$1.13M to -$1.03M.